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Abstract
Background—Individuals co-infected with Kaposi’s sarcoma herpesvirus (KSHV) and Human
Immunodeficiency Virus (HIV) are at greatly increased risk of developing Kaposi’s sarcoma (KS).
The objective of the current analysis is to identify risk cofactors, for KS among HIV-positive
individuals.
Methods—We conducted a case-control study of KS in Cameroon on 161 HIV-positive and 14
HIV-negative cases and 680 HIV-positive and 322 HIV-negative controls. Participants answered a
physician-administered questionnaire and provided blood and saliva specimens. Antibodies
against KSHV lytic, K8.1, and latent, ORF73, antigens were measured by ELISA to determine
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KSHV serostatus. Conditional logistic regression was performed to determine multivariate odds
ratios (OR) and 95% confidence intervals (CI) for risk factors associated with KS among HIV-
positive cases and controls.
Results—Overall, 98% (158) of HIV-positive cases, 100% (14) of HIV-negative cases, 81%
(550) of HIV-positive controls, and 80% (257) of HIV-negative controls were KSHV seropositive.
Risk factors for KS among HIV-positive individuals included KSHV seropositivity (OR=9.6; 95%
CI 2.9, 31.5), non-use of a mosquito bed net (OR 1.9; 95% CI 1.2, 2.9), minority ethnicity
(OR=3.1; 95% CI 1.1, 9.3), treatment from a traditional healer (OR=2.3; 95% CI 1.5, 3.7), history
of transfusion (OR=2.4; 95% CI 1.5, 3.9), and family history of cancer (OR=1.9; 95% CI 1.1, 3.1).
Conclusion—KSHV seroprevalence of ≥80% indicates a high prevalence in the general
population in Cameroon. Among HIV-positive individuals, the strong association of KS with non-
use of mosquito nets and treatment from traditional healers are compelling findings, consistent
with recently reported data from East Africa.
Keywords
Kaposi’s sarcoma (KS); Kaposi’s sarcoma herpesvirus (KSHV); Human herpesvirus 8 (HHV-8);
Human Immunodeficiency Virus (HIV); risk factors; Cameroon
Introduction
Kaposi’s sarcoma (KS) is the most prevalent HIV and AIDS associated cancer worldwide
[1–3]. Until the advent of the AIDS epidemic, KS was found in specific populations, notably
individuals from equatorial Africa (endemic KS), older men from Eastern Europe and the
Mediterranean (classic KS), and individuals who received an organ transplant or were
immune-compromised (iatrogenic KS) [2].
Epidemic KS is considered the most common AIDS-associated malignancy [1,4], with an
increased risk among HIV-positive individuals with lowered immune status [5,6]. Since the
advent of combined anti-retroviral therapy (cART), the prevalence of epidemic KS has
dramatically decreased in high income countries [5,7]. In Africa, however, KS continues to
be one of the leading AIDS-defining illnesses, as well as one of the most prevalent cancers
overall [3].
The etiologic agent that causes KS, human herpesvirus 8 (HHV-8), also known as Kaposi’s
sarcoma herpesvirus (KSHV), was discovered in 1994 [8]. The presence of KSHV alone,
however, is not sufficient for the development of KS disease: a large proportion of
individuals with KSHV never develop KS [6,9,10]. KSHV is transmitted chiefly via saliva
[11–14], but the modes of transmission are likely different in different populations. In low
KSHV prevalence areas, such as the US, KSHV mainly infects men who have sex with men
(MSM), implicating risk factors related to sexual behavior [15]. In some regions of Africa,
KSHV is very prevalent in the general population and increases with age beginning in
childhood [16], suggesting that transmission is via non-sexual horizontal routes [14].
Cameroon is located within the “KS belt”, the region along the equator in Africa that has the
highest incidence of KS worldwide [17]. Endemic KS has been localized in areas of high
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altitude, cooler temperatures, and moderate rainfall [18], conditions found in the Northwest
and Southwest regions of Cameroon. Countries in the KS belt generally have higher KSHV
prevalence compared to elsewhere in Africa [17,19]. In areas outside of the KS belt,
geographic pockets of high KSHV prevalence do not seem to systematically present with
high KS rates [19].
Cameroon has been reported to have one of the highest prevalence of KSHV in the world
(62%) [20], as well as the highest prevalence of HIV in Western and Central Africa (5.3%)
[21]. While prevalence estimates of epidemic KS in Cameroon vary [20,22] KS is one of the
most commonly diagnosed cancers among men and women and is estimated to comprise
15–20% of all adult cancers [18]. The combination of the overall high prevalence of KSHV,
geographic and environmental risk factors found in endemic KS regions, and the HIV
epidemic in Cameroon, likely contribute to the high rates of KS [20,23,24].
To date, most prospective research on risk factors on AIDS-related KS has been conducted
in East or Southern Africa. Little research of AIDS-related KS has been conducted in
Central or West Africa, despite the intersection of known environmental and etiologic risk
factors in this region. We report here results of a case-control study, including determination
of KSHV seroprevalence and examination of risk factors for KS among HIV-positive
individuals in Cameroon.
Materials & Methods
In 2005, the National Institute of Allergy and Infectious Diseases (NIAID) funded the
International Epidemiologic Databases to Evaluate AIDS (IeDEA) to identify
epidemiological trends and answer evolving research questions associated with HIV using
large cohort studies [25]. In 2006, the National Cancer Institute (NCI) provided additional
funding to study HIV-associated cancers. Yaoundé, Cameroon served as the sentinel site for
cancer research in IeDEA-Central Africa, through its collaboration with the Oncology
Department of the General Hospital of Yaoundé and with Solidarité Chimiotherapie
(SOCHIMIO), the largest non-governmental organization providing support to cancer
patients in Cameroon.
Study Design
This prospective, matched case-control study nested within IeDEA-Central Africa, was
conducted from 2009–2011, with the primary aim to identify risk factors for the
development of KS among HIV-positive and HIV-negative individuals. Cases were
identified amongst patients in the IeDEA cohort who presented with signs and symptoms of
KS, through the SOCHIMIO cancer registry, and amongst referrals to the Oncology
Department of the General Hospital of Yaoundé. Trained cancer specialists confirmed KS
diagnosis through clinical examination, and, if necessary, a skin biopsy. HIV-positive and
HIV-negative controls were identified by referring physicians through the HIV Care and
Treatment Centers and Voluntary Testing and Counseling Centers at the General Hospital
and the Military Hospital, both IeDEA sites in Yaoundé. To be eligible, all participants were
required to be 21 years of age or older, to have resided in Cameroon for at least 6 months
prior to enrollment, and to provide written informed consent. The study was designed so that
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four HIV-positive controls and two HIV-negative controls were matched to each KS case
based on sex and 5-year age brackets. The protocol was reviewed and approved by the
Cameroon National Ethics Committee and the Institutional Review Board (IRB) at RTI
International.
Data collection
Physicians conducted a clinical examination and interview with each participant. A
standardized questionnaire (see supplementary table 1) collected detailed information on
potential risk factors for KS, including demographics, socio-economic status, environmental
exposure, health-risk behaviors, reproductive health history, concurrent immunosuppressive
conditions, and medical history. For HIV-positive cases and controls, information was also
collected on suspected mode of HIV transmission and time since confirmed HIV infection.
Additional clinical data on antiretroviral therapy (ART) was derived from a transfer form
completed by the referring physician.
Clinical specimens and KSHV diagnosis
Whole blood, serum and saliva samples were collected from all participants at enrollment
into the study. All specimen samples were shipped to the Viral Oncology Section at the
Frederick National Laboratory for Cancer Research in Frederick, Maryland. Serum samples
were tested for antibodies against two recombinant KSHV antigens, K8.1 and ORF73 using
previously described ELISAs. ORF73 encodes LANA, which is expressed during latency
and K8.1 encodes a glycoprotein that is expressed during lytic infection. ELISA methods,
and relative interpretations, are described in [26].
Statistical analysis
Descriptive frequencies were obtained for key characteristics among cases and controls
stratified by HIV status. Results of assays for K8.1 and ORF73 were analyzed separately
and then combined: a subject was defined as seropositive for KSHV if they tested positive
for K8.1 or ORF73.
Conditional logistic regression was used to obtain odds ratios (OR) and 95% confidence
intervals (CI) for selected risk factors associated with KS status. Univariate analysis was
conducted on KSHV serostatus and 22 questionnaire covariates. The initial multivariate
model included variables with a significant unadjusted OR at α<.05 and variables found to
be associated with KS in the literature. HIV-related variables were excluded from the final
model due to the limited data available. The final multivariate model was selected using a
backwards stepwise algorithm. Data were analyzed using SAS v 9.2.
Results
Description of the Study Population
By the end of the enrollment period, we had accrued 175 cases, of which 161 (92%) were
HIV-positive (epidemic KS) and 14 (8%) were HIV-negative (endemic KS), and 1002
controls, 680 (68%) HIV-positive and 322 (32%) HIV-negative (Table 1). As expected, HIV
infection was strongly associated with KS risk (OR=5.45; 95% CI: 3.10, 9.56; p<.0001).
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The prevalence of KSHV was 98% (158/161) in HIV-positive cases, 100% (14/14) in HIV-
negative cases, 81% (550/680) in HIV-positive controls, and 80% (257/322) in HIV-
negative controls. Characteristics of all study participants are presented in detail in Table 1.
Risk Factors for KS among HIV-positive Individuals
Risk factors for KS were investigated in HIV-subjects. In the univariate analysis (Table 2),
KS was associated with a positive test to any or either KSHV antigen, presence of electricity
in the home, not sleeping under a mosquito net, and history of tobacco use (p<.05). KS was
also associated with having four or more lifetime sexual partners, inconsistent condom use,
history of a sexually transmitted infection (STI), treatment by a traditional healer, history of
a transfusion, family history of cancer, WHO HIV clinical stage of III or IV at the start of
antiretroviral therapy (ART), and duration of ART of less than 18 months (p<.05). We
analyzed variables found to be significant risk factors in other studies of KS, including the
color of the soil where the participant spent time as a child, going barefoot as a child, and
source of bathing water. However, none of these variables were shown to be significantly
associated with KS in this analysis.
In the multivariate analysis (Table 3), KSHV seropositivity remained highly associated with
KS disease (OR=9.6; 95% CI 2.9, 31.5; p=.0002). Not sleeping under a mosquito net
(OR=1.9; 95% CI 1.2, 2.9; p=.006), receiving treatment from a traditional healer (OR=2.3;
95% CI 1.5, 3.7; p=.0002), having a history of transfusion (OR=2.4; 95% CI 1.5, 3.9; p=.
0005), and a family history of cancer (OR=1.9; 95% CI 1.1, 3.1; p=.018) were positively
associated with KS.
Discussion
Cameroon is a highly informative country in which to study the co-infection of HIV and KS
because of the presence of environmental risk factors found in endemic KS areas and high
rates of both KSHV and HIV. No study of KS of this magnitude has ever been performed in
Cameroon or Central Africa, making this study the first of its kind. Our analysis revealed
several important risk factors for KS among HIV-positive individuals, alongside KSHV
seropositivity. In particular, use of a mosquito net and treatment from a traditional healer
were of greatest interest due to possible relationships with risk factors previously described
in the literature [27,28].
The majority of study participants, HIV-positive and HIV-negative, were KSHV
seropositive. The extremely high proportion of KSHV seropositivity in HIV-positive (81%),
and HIV-negative controls (80%), indicate that KSHV infection is likely much more
prevalent in the general population of Cameroon than previously understood.
A high proportion of participants from all groups (33%-50%) classified their work as
professional, indicating a higher socio-economic status. Higher SES have been associated
with both endemic, [29] and epidemic KS [30]. However, neither occupation nor education
was associated with KS among HIV-positive individuals in our study. In contrast,
participants without electricity in the home were moderately more likely to have KS
(OR=1.9; 95% CI 0.9, 4.5; p=.1028) as did participants who did not sleep under a mosquito
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net (OR=1.9; 95% CI 1.2, 2.9; p=.006). Although electricity in the home and use of a
mosquito net can indicate higher income and education [31,32] higher SES was not
associated with KS risk in our study, so use of a mosquito bed net represents some other
protective effect. Plasmodium parasitemia has previously been shown to be a risk factor for
KSHV infection [28], and a possible association between malaria and development of KS
merits further investigation.
We found that participants whose ethnic group was not classified as Bantu or Semi-bantu
were slightly more likely to have KS as compared to Semi-bantu (OR=3.1; 95% CI 1.1, 9.3;
p=.0702). Region of origin was highly correlated with ethnic group (Figure 1), and therefore
ethnicity may be a proxy for environmental exposure related to endemic KS risk.
Environmental cofactors reported in the literature include exposure to volcanic soils [18,33],
going barefoot [29] and exposure to surface water [30]. The Semi-bantu typically originate
from the cooler and drier western highlands (West and Northwest) and the Bantu from parts
of the coastal South and Southwest regions characterized by long rainy seasons. Other ethnic
groups typically live in the Northern regions, characterized by dry savanna (Extreme North)
or volcanic mountains and plateaus (Adamawa and North).
Individuals located in areas of high rainfall may be more susceptible to KS due to greater
exposure to surface water [34] or, potentially parasitic infections [28]. Although malaria is
endemic throughout Cameroon, the coastal South and Southwest regions have the highest
prevalence of malaria in the country [31,35]. Conversely, individuals in higher altitude
regions in the North may be more susceptible to KS due to increased exposure to volcanic
and iron-rich soils [18,36]. Although previous literature has shown an association between
KS and playing outside barefoot as children, we only found a marginal association in our
analysis (OR=2.8; 95% CI 0.8, 10.4). This association may be related to exposure to soil-
transmitted helminthes, e.g. hookworm, a common outcome of walking barefoot, which has
been shown to be associated with an increased prevalence of KSHV [28]. Malaria and
hookworm cause anemia, and thus tissue hypoxia, which is a known activator of KSHV
replication, which could promote KS [37]. Moreover, systemic parasitic infections can cause
profound immunological abnormalities that may alter cellular immune responses to KSHV,
thus promoting KS [38,39].
On the other hand, the effect of ethnicity on the risk of KS development could be also due to
genetic factors. We do observe an association between KS and self-reported family history
of cancer (OR=1.8, 95% CI, 1.2, 2.7; p=.0178). The role of host genetic factors in the risk of
KS should be explored further.
We also found a significant association between KS and history of transfusion (OR=1.9,
95% CI 1.3, 3.8; p=.0005), and ever receiving treatment from a traditional healer (OR=2.4,
95% CI, 1.7, 2.4; p=.0002). Transfusion often occurs during hospitalization, which could
have resulted from advanced HIV or undiagnosed KS. While the risk of KS among those
who had transfusions should be explored further, the potential for unobserved confounding
must be kept into account. The association of KS and traditional medicine could be related
to the use of herbal products that when chewed or rubbed into the skin and mucosae may
contribute to the transmission of KSHV through saliva and/or promote the development of
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KS through abrasive micro-trauma to the skin [40]. A recent study on natural products that
promote KSHV reactivation found that 9 of the 28 most active plant extracts were from
West Africa and 3 of those were specifically from Cameroon [27]. Additional investigation
on traditional treatments may be warranted.
Heterosexual HIV exposure was moderately significantly associated with KS status (OR 1.9,
95% CI, 1.3, 2.7; p=.0571) as compared to other or unknown origin of exposure.
Heterosexual exposure is the most common modality of HIV transmission in Sub-Saharan
Africa [41]. However, the absence of associations between KS and number of lifetime
sexual partners or history of STIs reiterates the lack of evidence for sexual activity as a
major route of KSHV transmission [42].
Finally, although the number of HIV-negative cases in this study (14) was not enough to
provide statistically significant comparisons with the HIV-negative controls, they give us an
interesting look into the potential differences between endemic and epidemic KS in
Cameroon. Unlike the HIV-positive cases, the HIV-negative cases in our study were all
male, of older ages, and mostly farmers. All of the HIV-negative cases tested positive to
both KSHV antigens. This may be explained by an increase in the prevalence of
seropositivity to KSHV antigens in older age, or could reflect an AIDS related deterioration
of humoral immune responses in the HIV-positive cases.
Conclusion
This matched case-control study of KS among HIV-negative and HIV-positive participants
in Cameroon is the first of its kind. The high prevalence of KSHV in both HIV-positive and
HIV-negative participants indicates a notably higher prevalence of KSHV in the general
population of Cameroon than previously understood. Multivariate risk factors for KS among
HIV-positive participants included KSHV infection and cofactors, such as lack of mosquito
bed net use, minority ethnicity, treatment by a traditional healer, history of transfusion,
family history of cancer, and heterosexual origin of HIV infection. More research is needed
to understand how the interactions of these risk factors with KSHV and HIV infection
increase the risk of KS disease.
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Table 1
Descriptive characteristics of HIV-positive and HIV-negative KS cases and controls









Total N 161 14 680 322
KSHV seropositivity
 K8.1 positive 154 (95.7) 14 (100.0) 527 (77.5) 241 (74.8)
 Orf 73 positive 145 (90.1) 14 (100.0) 486 (71.5) 214 (66.5)
 Overall positive 158 (98.1) 14 (100.0) 550 (80.9) 257 (79.8)
Proportion Male 91 (56.5) 14 (100.0) 407 (59.9) 188 (58.4)
Age range in years
 19–29 21 (13.0) 2 (14.3) 83 (12.2) 43 (13.4)
 30–39 67 (41.6) 1 (7.1) 276 (40.6) 139 (43.2)
 40–49 45 (28.0) 3 (21.4) 190 (27.9) 82 (25.5)
 ≥50 28 (17.4) 8 (57.1) 131 (19.3) 58 (18.0)
Occupation
 Professional 52 (32.5) 6 (42.9) 232 (34.2) 158 (49.1)
 Semi-skilled 21 (13.1) 0 (0.0) 101 (14.9) 33 (10.2)
 Trader/sales 29 (18.1) 1 (7.1) 172 (25.4) 48 (14.9)
 Farmer 13 (8.1) 4 (28.6) 34 (5.0) 10 (3.1)
 Unemployed 45 (28.1) 3 (21.4) 139 (20.5) 73 (22.7)
Marital status
 Single/Divorced/Widowed 77 (47.8) 4 (28.6) 272 (40.0) 115 (35.7)
 Married 70 (43.5) 9 (64.3) 319 (46.9) 170 (52.8)
 Open relationship 14 (8.7) 1 (7.1) 89 (13.1) 37 (11.5)
Educational Attainment
 None/primary 34 (21.1) 4 (28.6) 155 (22.8) 54 (16.8)
 Secondary 96 (59.6) 6 (42.9) 363 (53.5) 192 (59.6)
 Higher 31 (19.3) 4 (28.6) 161 (23.7) 76 (23.6)
Region of origin
 Littoral 9 (5.7) 1 (7.1) 32 (4.8) 30 (9.4)
 South (South, Center, East) 98 (62.4) 8 (57.1) 358 (53.5) 126 (39.4)
 West (West, NW, SW) 45 (28.7) 5 (35.7) 253 (37.8) 141 (44.1)
 North (North, Adamawa, Extreme North) 5 (3.2) 0 (0.0) 26 (3.9) 23 (7.2)
Ethnic group
 Bantu 108 (67.1) 9 (64.3) 395 (58.1) 161 (50.0)
 Semi-bantu 45 (28.0) 5 (35.7) 255 (37.5) 139 (43.2)
 Other 8 (5.0) 0 (0.0) 30 (4.4) 22 (6.8)
KS = Kaposi’s Sarcoma
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HIV = Human Immunodeficiency Virus
N = Number
KSHV = Kaposi’s Sarcoma Herpesvirus
Overall positive = Defined as having a positive test to either or both K8.1 and Orf73 ELISA tests.
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Table 2
Unadjusted odds ratios (OR) and 95% confidence intervals (CI) of KS risk factors among HIV-positive cases







Total N 161 680
KSHV serostatusa
 K8.1 positive 154 (95.7) 527 (77.5) 6.3 (2.9,13.7)*
 Orf 73 positive 145 (90.1) 486 (71.5) 3.6 (2.1,6.2)*
 Overall positive 158 (98.1) 550 (80.9) 12.3 (3.9,39.0)*
Occupation
 Professional 52 (32.5%) 232 (34.2%) 0.7 (0.4,1.2)
 Semi-skilled 21 (13.1%) 101 (14.9%) 0.7 (0.4,1.3)
 Trader/sales 29 (18.1%) 172 (25.4%) 0.5 (0.3,0.9)*
 Farmer 13 (8.1%) 34 (5%) 1.2 (0.6,2.6)
 Unemployed 45 (28.1%) 139 (20.5%) 1.0
Marital status
 Single/Divorced/Widowed 77 (47.8%) 272 (40%) 1.3 (0.8,1.9)
 Married 70 (43.5%) 319 (46.9%) 1.0
 Open relationship 14 (8.7%) 89 (13.1%) 0.7 (0.4,1.3)
Education attainment
 None/primary 34 (21.1%) 155 (22.8%) 1.1 (0.64,1.93)
 Secondary 96 (59.6%) 363 (53.5%) 1.4 (0.86,2.12)
 Higher 31 (19.3%) 161 (23.7%) 1.0
House has electricity
 Yes 146 (90.7) 646 (95.0) 1.0
 No 15 (9.3) 34 (5.0) 1.9 (1.01,3.6)*
Participant sleeps under a mosquito net
 Yes 64 (40.0) 344 (50.6) 1.0
 No 96 (60.0) 336 (49.4) 1.5 (1.1,2.2)*
Region of origin
 Littoral 9 (5.7) 32 (4.8) 1.6 (0.7,3.5)
 South (South, Center, East) 98 (62.4) 359 (53.5) 1.5 (1.0,2.3)*
 West (West, NW, SW) 45 (28.7) 253 (37.8) 1.0
 North (North, Adamawa, Extreme North) 5 (3.2) 26 (3.9) 1.1 (0.4,3.1)
Ethnic group
 Bantu 108 (67.1) 395 (58.1) 1.5 (1.1,2.3)*
 Semi-bantu 45 (28.0) 255 (37.5) 1.0
 Other 8 (5.0) 30 (4.4) 1.6 (0.7,3.6)





























History of tobacco use
 Yes 50(31.1) 167 (24.6) 1.6 (1.1,2.5)*
 No 111 (68.9) 512 (75.4) 1.0
History of alcohol use 161 680
 Yes 128 (79.5) 479 (70.4) 1.8 (1.2,2.8)*
 No 33 (20.5) 201 (29.6) 1.0
Color of soil where spent time as a child
 Black 30 (18.9) 106 (15.8) 1.2 (0.8,1.9)
 Brown 17 (10.7) 94 (14.0) 0.8 (0.4,1.4)
 Red 103 (64.8) 437 (64.9) 1.0
 White 9 (5.7) 36 (5.3) 1.1 (0.5,2.3)
As a child, how often did you play outside barefoot
Ever (Always/Most of the time/Often/Rarely) 153 (96.8) 637 (95.1) 1.6 (0.6,4.2)
 Never 5 (3.2) 33 (4.9) 1.0
Source of water - bathing
 Private source 58 (36.0) 219 (32.2) 1.0
 Communal source 86 (53.4) 386 (56.8) 0.8 (0.6,1.2)
 Surface water source 17 (10.6) 75 (11.0) 0.8 (0.4,1.4)
No. of regular sexual partners (lifetime)
 0–1 49 (32.0) 201 (31.4) 1.0
 2–3 36 (23.5) 214 (33.4) 0.7 (0.4,1.1)
 4+ 68 (44.4) 226 (35.3) 1.3 (0.8,1.9)
History of condom use
 Never 18 (15.0) 61 (11.4) 2.0 (1.0,4.0)*
 Sometimes 53 (44.2) 191 (35.8) 2.0 (1.2,3.4)*
 Most of the time 22 (18.3) 80 (15.0) 2.0 (1.1,3.8)*
 Always 27 (22.5) 201 (37.7) 1.0
History of an STI
 Yes 108 (68.4) 288 (57.8) 1.7 (1.1,2.4)*
 No 50 (31.6) 283 (42.2) 1.0
Received treatment from a traditional healer
 Yes 106 (65.8) 304 (44.7) 2.4 (1.7,3.5)*
 No 55 (34.2) 376 (55.3) 1.0
History of transfusion
 Yes 46 (28.9) 120 (17.8) 1.9 (1.3,2.8)*
 No 113 (71.1) 556 (82.2) 1.0
Family history of cancer





























 Yes 37 (24.8) 101 (15.3) 1.8 (1.2,2.7)*
 No 112 (75.2) 560 (84.7) 1.0
Origin of HIV exposure
 Heterosexual sex 87 (54.0) 266 (39.3) 1.9 (1.3,2.7)*
 Other/Unknown 74 (46.0) 410 (60.7) 1.0
History of ART
 Yes 88 (84.6) 457 (84.5) 0.9 (0.5,1.7)
 No 16 (15.4) 84 (15.5) 1.0
HIV Clinical Stage at the start of ART
 I–II 10 (28.6) 96 (61.5) 1.0
 III–IV 25 (71.4) 60 (38.5) 3.8 (1.7,8.6)*
Duration of ART
 <6.5 months 39 (44.3) 69 (15.3) 5 (2.9,8.6)*
 6.5–18 months 16 (18.2) 80 (17.8) 2.0 (1.0,3.9)*




Referent group for KSHV serostatus is KSHV seronegative.
KS = Kaposi’s Sarcoma
N = number
KSHV = Kaposi’s Sarcoma Herpesvirus
Overall positive = Defined as having a positive test to either or both K8.1 and Orf73 ELISA tests.
STI = Sexually Transmitted Infection
HIV = Human Immunodeficiency Virus
ART = Anti-retroviral Therapy
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Table 3
Multivariate odds ratios (OR) and 95% confidence intervals (CI) of KS risk factors among HIV-seropositive








Total N 161 680
KSHV serostatusa
 K8.1 positive 154 (95.7) 527 (77.5) ---1
 Orf 73 positive 145 (90.1) 486 (71.5) ---
 Overall positiveb 158 (98.1) 550 (80.9) 9.6 (2.9, 31.5)*
House has electricity
 Yes 146 (90.7) 646 (95.0) 1.0
 No 15 (9.3) 34 (5.0) 1.9 (0.9, 4.5)
Participant sleeps under a mosquito net
 Yes 64 (40.0) 344 (50.6) 1.0
 No 96 (60.0) 336 (49.4) 1.9 (1.2,2.9)*
Region of originc ---
Ethnic group
 Bantu 108 (67.1) 395 (58.1) 1.5 (0.9,2.4)
 Semi-bantu 45 (28.0) 255 (37.5) 1.0
 Other 8 (5.0) 30 (4.4) 3.1 (1.1,9.3)*
History of tobacco use
 Yes 50(31.1) 167 (24.6) 1.1 (0.7,1.9)
 No 111 (68.9) 512 (75.4) 1.0
History of alcohol use 161 680
 Yes 128 (79.5) 479 (70.4) 1.4 (0.8,2.5)
 No 33 (20.5) 201 (29.6) 1.0
Color of soil where spent time as a child
 Black 30 (18.9) 106 (15.8) 1.5 (0.8,2.7)
 Brown 17 (10.7) 94 (14.0) 0.8 (0.4,1.6)
 Red 103 (64.8) 437 (64.9) 1.0
 White 9 (5.7) 36 (5.3) 1.1 (.5,2.5)
As a child, how often did you play outside barefoot
 Ever (Always/Most of the time/Often/Rarely) 153 (96.8) 637 (95.1) 2.8 (0.8,10.4)
 Never 5 (3.2) 33 (4.9) 1.0
Source of water - bathing
 Private source 58 (36.0) 219 (32.2) 1.0
 Communal source 86 (53.4) 386 (56.8) 0.9 (0.6,1.5)





























 Surface water source 17 (10.6) 75 (11.0) 0.7 (0.3,1.4)
No. of regular sexual partners (lifetime)
 0–1 49 (32.0) 201 (31.4) 1.0
 2–3 36 (23.5) 214 (33.4) 0.8 (0.4,1.4)
 4+ 68 (44.4) 226 (35.3) 1.1 (0.7,1.9)
History of condom used ---
History of an STI
 Yes 108 (68.4) 288 (57.8) 1.2 (.8,1.9)
 No 50 (31.6) 283 (42.2) 1.0
Received treatment from a traditional healer
 Yes 106 (65.8) 304 (44.7) 2.3 (1.5,3.7)*
 No 55 (34.2) 376 (55.3) 1.0
History of transfusion
 Yes 46 (28.9) 120 (17.8) 2.4 (1.5,3.9)*
 No 113 (71.1) 556 (82.2) 1.0
Family history of cancer
 Yes 37 (24.8) 101 (15.3) 1.9 (1.1,3.1)*
 No 112 (75.2) 560 (84.7) 1.0
Origin of HIV exposure
 Heterosexual sex 87 (54.0) 266 (39.3) 1.5 (1.0,2.4)*
 Other/Unknown 74 (46.0) 410 (60.7) 1.0
History of ARTe ---
HIV Clinical Stage at the start of ARTe ---




Referent group for KSHV serostatus is KSHV seronegative.
b
The multivariate model included only the variable for “overall” KSHV serostatus, for individuals who were positive for either K8.1 or Orf73
antigens.
c
Region of origin was not included in multivariate model because highly correlated with ethnic group.
d
History of condom use was not included in the multivariate model because only those who responded “yes” to any sexual activity in the last 12
months answered the question about frequency of condom use.
e
History of ART, HIV Clinical Stage at the start of ART, and duration of ART, were not included in the multivariate model due to unavailability of
ART information for many participants.
KS = Kaposi’s Sarcoma
N = number
KSHV = Kaposi’s Sarcoma Herpesvirus
Overall positive = Defined as having a positive test to either or both K8.1 and Orf73 ELISA tests.
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STI = Sexually Transmitted Infection
HIV = Human Immunodeficiency Virus
ART = Anti-retroviral Therapy
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